Dr. Reddy's receives approval for aspirin and extended-release dipyridamole
Dr. Reddy’s Laboratories Ltd. has announced receipt of approval from the US FDA for aspirin and extended-release dipyridamole capsules in the US market. The drug is a therapeutic equivalent generic version of Aggrenox capsules from Boehringer Ingelheim, and will be made available in 25 mg/200 mg strength with 60 count bottle size.
The Aggrenox brand and generic had US sales of approximately $183-mn for the most recent 12 months ending in August 2018 according to IMS Health.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-01
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
West Asia Tensions Squeeze Pharma Raw Materials
-
India Strengthens Drug Approval Oversight with Expanded CDSCO Powers
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
Strides Pharma Reports Strong Q2 as Net Profit Surges 82%
-
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
-
U.S. Health Chief Says No Evidence Linking Tylenol to Autism
Recommend Reading
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Novo Nordisk Faces $46 Billion Windfall Threatened by Wegovy Missteps and Eli Lilly’s Rise
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
Biological E Partners with Recbio to Bring HPV9 Vaccine to India and Global Markets
-
What Are Hydrolysis, Oxidation, and Condensation?
-
Behind Arkema’s ￥430 Million Claim: A Patent War Over Acrylic Acid Is Tearing Off the “Technical Fig Leaf” of China’s Chemical Giants
-
Aniline: Applications, Hazards, and Safety Guide in Industrial Use
-
FDA’s Review of BHT and ADA Signals a New Era for Food Additive Compliance
-
Congo Copper and Cobalt Miners Are Being Forced to Cut Chemical Use as Middle East Conflict Hits the New Energy Supply Chain